Performance of CHA 2 DS 2 -VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer.
Alyaa M AjabnoorSalwa S ZghebiRosa ParisiDarren M AshcroftCorinne Faivre-FinnMamas Andreas MamasEvangelos KontopantelisPublished in: European heart journal open (2024)
-VASc performs similarly in predicting stroke to AF patients without cancer. Our findings highlight the importance of cancer diagnosis during the development of risk scores and opportunities to optimize the HAS-BLED risk score to better serve cancer patients with AF.
Keyphrases
- atrial fibrillation
- papillary thyroid
- squamous cell
- left atrial
- oral anticoagulants
- catheter ablation
- heart failure
- left atrial appendage
- direct oral anticoagulants
- end stage renal disease
- percutaneous coronary intervention
- childhood cancer
- lymph node metastasis
- newly diagnosed
- chronic kidney disease
- ejection fraction
- young adults
- venous thromboembolism
- brain injury